TC BioPharm ^Companies

TC BioPharm is a publicly traded, clinical-stage cell therapy company that develops advanced allogeneic CAR-T cell therapy products for the treatment of cancer. Their mission is to bring improved medicines to patients quickly by creating efficient product development and clinical translation processes. They have a diverse team of interdisciplinary scientists optimizing new product candidates in their state-of-the-art research complex. TC BioPharm is currently conducting Phase II/III clinical studies of their lead product, ImmuniCell, in renal cell carcinoma, non-small cell lung cancer, and melanoma patients. They work directly with physicians and hospitals around the world to provide quality-controlled products.